

| | | | | | |
|---|---------------------|----|---|--------------------------|----------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/828,474 |
| | | | | Filing Date | April 20, 2004 |
| | | | | First Named Inventor | Tianmin Zhu |
| | | | | Group Art Unit | 1612 |
| Examiner Name | Benjamin J. Packard | | | | |
| Sheet | 1 | of | 1 | Attorney Docket Number | AM101007 |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|----------|----------------------|----------------------|---|---|---|
| | | Number (If known) | Kind Code (If Known) | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
|--------------------|----------|-------------------------|--------|----------------------|---|---|---|---|
| | | Office | Number | Kind Code (If Known) | | | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|--------------------|----------|--|--------------------------|
| | 1. | NG et al., "Wortmannin Inhibits PKB/Akt Phosphorylation and Promotes Gemcitabine Antitumor Activity in Orthotopic Human Pancreatic Cancer Xenografts in Immunodeficient Mice" <i>Clinical Cancer Research</i> – Vol. 7 (Oct 2001) pp 3269-3275. | <input type="checkbox"/> |
| | 2. | WHALIN et al., "The Use Of Rapamycin And Wortmannin In The Dissection Of The Signal Transduction Pathways Regulating The Phosphorylation Of The Ribosomal Protein S6" <i>Toxin and Signal Transduction</i> – Harwood Academic Publishers, Amsterdam (1997) pp 427-455. | <input type="checkbox"/> |
| | 3. | SCHULTZ et al., "In Vitro and in Vivo Antitumor Activity of the Phosphatidylinositol-3-kinase Inhibitor, Wortmannin" <i>Anticancer Research</i> – Vol. 15 (1995) pp 1135-1140. | <input type="checkbox"/> |
| | 4. | YU et al., "PWT-458, a Novel Pegylated- 17-Hydroxywortmannin, Inhibits Phosphatidylinositol 3-Kinase Signaling and Suppresses Growth of Solid Tumors" <i>Cancer Biology & Therapy</i> – Vol. 4 (May 2005) pp 538-545. | <input type="checkbox"/> |
| | 5. | SAMUELS et al., "Inhibiting Phosphoinositide 3-Kinases" <i>Cancer Biology & Therapy</i> Vol. 4 (May 2005) pp 546-547. | <input type="checkbox"/> |
| | 6. | SATO et al., "Effects of Wortmannin Analogs on Bone in Vitro and in Vivo" <i>The Journal of Pharmacology and Experimental Therapeutics</i> Vol. 277 (1996) pp 543-550. | <input type="checkbox"/> |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.